Sfoglia per Autore
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer
2025 Zapata Dongo, R; Fontana, D; Mologni, L; Faya Castillo, J; Infante, V
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer
2025 Zapata Dongo, R; Fontana, D; Mologni, L; Faya Castillo, J; Infante Varillas, S
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis
2025 Malighetti, F; Villa, M; Villa, A; Pelucchi, S; Aroldi, A; Cortinovis, D; Canova, S; Capici, S; Cazzaniga, M; Mologni, L; Ramazzotti, D; Cordani, N
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors
2025 Villa, M; Malighetti, F; De, S; Villa, A; Cordani, N; Aroldi, A; Antoniotti, M; Caravagna, G; Graudenzi, A; Piazza, R; Mologni, L; Ramazzotti, D
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0)
2025 Crippa, V; Cordani, N; Villa, A; Malighetti, F; Villa, M; Sala, L; Aroldi, A; Piazza, R; Cortinovis, D; Mologni, L; Ramazzotti, D
A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma
2025 Pattabiraman, N; Lobello, C; Rushmore, D; Mologni, L; Wasik, M; Basappa, J
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer
2025 Zapata Dongo, R; Poterico, J; Fontana, D; Mologni, L; Alvarez-Chacon, C; Rojas-Armas, J; Calla, J
α-Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML
2025 Introvigne, M; Destro, L; Mologni, L; Crippa, V; Zardi, P; Fini, F; Prati, F; Caselli, E; Zambon, A
Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of acute myeloid leukemia
2025 Destro, L; Crippa, V; Gabbia, D; Roverso, M; Bogialli, S; Zardi, P; Marzaro, G; Mologni, L; Zambon, A
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
2025 Villa, M; Cazzaniga, G; Bolognesi, M; Malighetti, F; Crippa, V; Aroldi, A; Bozzini, G; Pagni, F; Piazza, R; Mologni, L; Ramazzotti, D
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype
2025 Civettini, I; Zappaterra, A; Corti, P; Messina, A; Aroldi, A; Biondi, A; Cavalca, F; Crippa, V; Crosti, F; Ferrari, G; Malighetti, F; Mologni, L; Piperno, A; Ramazzotti, D; Scollo, C; Zambon, A; Rossi, F; Gambacorti-Passerini, C
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer
2025 Crippa, V; Cordani, N; Villa, A; Malighetti, F; Villa, M; Sala, L; Aroldi, A; Piazza, R; Cortinovis, D; Mologni, L; Ramazzotti, D
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
2024 Fontana, D; Malighetti, F; Villa, M; Zambon, A; Gambacorti-Passerini, C; Mologni, L
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition
2024 Zapata-Dongo, R; Fontana, D; Mologni, L; Faya-Castillo, J; Silva-Torres, F; Moy-Diaz, B; Infante-Varillas, S
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
2024 Fontana, D; Malighetti, F; Villa, M; Zambon, A; Gambacorti-Passerini, C; Mologni, L
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
2024 Villa, M; Malighetti, F; Sala, E; Sharma, G; Arosio, G; Gemelli, M; Manfroni, C; Fontana, D; Cordani, N; Meneveri, R; Zambon, A; Piazza, R; Pagni, F; Cortinovis, D; Mologni, L
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma
2024 Villa, M; Geeta, G; Malighetti, F; Mauri, M; Arosio, G; Cordani, N; Lobello, C; Larose, H; Pirola, A; D'Aliberti, D; Massimino, L; Criscuolo, L; Pagani, L; Chinello, C; Mastini, C; Fontana, D; Bombelli, S; Meneveri, R; Lovisa, F; Mussolin, L; Janikova, A; Pospíšilová, Š; Turner, S; Inghirami, G; Magni, F; Urso, M; Pagni, F; Ramazzotti, D; Piazza, R; Chiarle, R; Gambacorti-Passerini, C; Mologni, L
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer
2024 Crippa, V; Fontana, D; Civettini, I; Mologni, L; Piazza, R; Gambacorti Passerini, C; Ramazzotti, D
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis
2024 Crespiatico, I; Zaghi, M; Mastini, C; D'Aliberti, D; Mauri, M; Mercado, C; Fontana, D; Spinelli, S; Crippa, V; Inzoli, E; Manghisi, B; Civettini, I; Ramazzotti, D; Sangiorgio, V; Gengotti, M; Brambilla, V; Aroldi, A; Banfi, F; Barone, C; Orsenigo, R; Riera, L; Riminucci, M; Corsi, A; Breccia, M; Morotti, A; Cilloni, D; Roccaro, A; Sacco, A; Stagno, F; Serafini, M; Mottadelli, F; Cazzaniga, G; Pagni, F; Chiarle, R; Azzoni, E; Sessa, A; Gambacorti Passerini, C; Elli, E; Mologni, L; Piazza, R
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies
2024 Malighetti, F; Villa, M; Mauri, M; Piane, S; Crippa, V; Crespiatico, I; Cocito, F; Bossi, E; Steidl, C; Civettini, I; Scollo, C; Ramazzotti, D; Gambacorti-Passerini, C; Piazza, R; Mologni, L; Aroldi, A
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile